Eyestem Research
PrivateLast Round
Series B
Aug 11, 2025
Est. Valuation
$67M
Total Funding Raised
$16.47M
Company Overview
Eyestem Research operates in Healthcare & Life Sciences and is based in Bangalore. Its latest recorded funding round was a Series B round in August 2025.
Eyestem Research is a clinical-stage biotechnology company developing scalable cell replacement therapies for incurable eye diseases, with a lead product targeting Dry Age-related Macular Degeneration (AMD).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Eyestem Research Comparables
Compare Eyestem Research with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Luxa Biotechnology | 85% | |
| Regenerative Patch Technologies | 84% | |
| Opsis Therapeutics | 80% |
For institutional investors. Book with your work email.
Eyestem Research Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Aug 11, 2025 | ||||
| Series A | Aug 8, 2022 | ||||
| Seed | May 26, 2021 | ||||
| Seed | Jan 7, 2021 | ||||
| Seed | Jan 20, 2020 | ||||
Seed | Jul 25, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Eyestem Research Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Endiya Partners | Series B, Series A, Seed |
| Kotak Mahindra Trustee | Seed, Series A |
| HealthCrest | Seed |
| Kotak Alternate Asset Managers | Seed, Series A |
| Centre for Cellular and Molecular Platforms | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 11, 2025
$10M round with a $57M pre-money valuation.
- Aug 11, 2025
$10M raised to advance investigational cell therapy.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingOct 7, 2026
Eyestem Research Private Limited is developing Eyecyte-RPE(TM), a stem cell-derived cell therapy that replaces lost retinal pigment epithelium cells for geographic atrophy, and presents promising interim Phase 2 results in Austria on Oct 7th '26.
- attends_eventOct 5, 2026
Eyestem Research Private Limited presents interim Phase 2 data for Eyecyte-RPE, showing continuing visual acuity gains in Geographic Atrophy, at EURetina 2026 conference in Austria on Oct 5th '26.
For institutional investors. Book with your work email.
Eyestem Research Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Eyestem Research's valuation, stock price, and market status.
Is Eyestem Research a public or private company?
Eyestem Research is a private company.
What is the current stock price of Eyestem Research?
Eyestem Research is a private company, so its shares have no public market price. Caplight tracks Eyestem Research's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Eyestem Research worth (valuation)?
Eyestem Research's valuation is estimated at $67.0M based on funding round data.
Can I buy Eyestem Research stock?
Eyestem Research shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Eyestem Research's last funding round?
Eyestem Research's most recent funding round was Series B on August 11, 2025.
Who are the main investors in Eyestem Research?
Key investors in Eyestem Research include Endiya Partners, Kotak Mahindra Trustee, HealthCrest, Kotak Alternate Asset Managers, Centre for Cellular and Molecular Platforms.
Will Eyestem Research IPO soon?
No public IPO plans have been announced for Eyestem Research.
How can I track Eyestem Research secondary market activity?
Caplight tracks bids, offers, and trades in Eyestem Research's shares on secondary markets.